Research Article

Serum Metabolite Biomarkers Discriminate Healthy Smokers from COPD Smokers

Qiuying Chen1, Ruba S. Deeb2, Yuliang Ma1, Michelle R. Staudt2, Ronald G. Crystal2*, Steven S. Gross1*

1 Department of Pharmacology, Weill Cornell Medicine, 1300 York Avenue, New York, NY, 10065, United States of America, 2 Department of Genetic Medicine, Weill Cornell Medicine, 1300 York Avenue, New York, NY, 10065, United States of America

* ssgross@med.cornell.edu (RGC); geneticmedicine@med.cornell.edu (SSG)

Abstract

COPD (chronic obstructive pulmonary disease) is defined by a fixed expiratory airflow obstruction associated with disordered airways and alveolar destruction. COPD is caused by cigarette smoking and is the third greatest cause of mortality in the US. Forced expiratory volume in 1 second (FEV1) is the only validated clinical marker of COPD, but it correlates poorly with clinical features and is not sensitive enough to predict the early onset of disease. Using LC/MS global untargeted metabolite profiling of serum samples from a well-defined cohort of healthy smokers (n = 37), COPD smokers (n = 41) and non-smokers (n = 37), we sought to discover serum metabolic markers with known and/or unknown molecular identities that are associated with early-onset COPD. A total of 1,181 distinct molecular ions were detected in 95% of sera from all study subjects and 23 were found to be differentially-expressed in COPD-smokers vs. healthy-smokers. These 23 putative biomarkers were differentially-correlated with lung function parameters and used to generate a COPD prediction model possessing 87.8% sensitivity and 86.5% specificity. In an independent validation set, this model correctly predicted COPD in 8/10 individuals. These serum biomarkers included myoinositol, glycerophosphoinositol, fumarate, cysteinesulfonic acid, a modified version of fibrinogen peptide B (mFBP), and three doubly-charged peptides with undefined sequence that significantly and positively correlate with mFBP levels. Together, elevated levels of serum mFBP and additional disease-associated biomarkers point to a role for chronic inflammation, thrombosis, and oxidative stress in remodeling of the COPD airways. Serum metabolite biomarkers offer a promising and accessible window for recognition of early-stage COPD.

Introduction

Chronic obstructive pulmonary disease (COPD) is a debilitating cigarette smoking-associated disease and the third most common cause of death in the US. The natural history of COPD is marked by episodes of exacerbation, morbidity and ultimately, mortality [1]. Other than O₂ inhalation, there are no therapies that diminish mortality of COPD [2]. To promote COPD
education and set universal standards of treatment, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) was initiated in 1998, and updated every year, incorporating the latest science for improving the lives of COPD patients around the world [3].

COPD is characterized by progressive restriction to expiratory airflow [4]. The forced expiratory volume in 1 second (FEV1) both defines and characterizes the severity of the disease, and is a well-known predictor of mortality [5]. However, COPD manifests itself with multiple phenotypes that cannot be identified through measurement of lung function alone. The importance of COPD risk assessment, phenotype identification, and early prognosis of exacerbation periods magnify the need for validated biomarkers in COPD [6]. A variety of promising biomarkers have been reported for COPD [7], including blood proteins [8–39], miRNAs [40, 41], and small molecule metabolites [42–50]. These proposed biomarkers are specifically associated with different aspects of COPD pathophysiology. Indeed, inflammatory markers in blood such as increased C-reactive protein [21, 33], fibrinogen [8, 9], IL-6 [34–36], IL-8 [37] and tumor necrosis factor alpha [38] have been linked to exacerbations and mortality, while reduced CC-16 [22] and elevated adiponectin [30, 31, 39] have been linked to lung function deficits and severity of emphysema. Notwithstanding rapidly expanding efforts to identify COPD biomarkers, especially blood proteins, no single marker has been adopted for routine clinical use to date.

Radiological markers, such as quantitative CT imaging have been used to define the COPD-related phenotype in smokers [51]. Gene expression [52, 53] and analysis of molecules in exhaled breath [54–56] have also been applied for potential discovery of COPD biomarkers. Most recently, metabolomics-based metabolite profiling has begun to attract attention as a biomarker discovery approach [57, 58]. Indeed, metabolites are the ultimate readout of disease phenotype and accordingly, metabolomics has proven to be a powerful tool for probing complex biological mixtures to discover changes in metabolite levels that arise from drug treatments, gene mutations and disease states. Paige et.al [48] analyzed plasma metabolite profiles from healthy non-smokers, smokers with emphysema, and smokers without emphysema, using ultra high performance liquid chromatography/quadrupole–time-of-flight mass spectrometry (UPLC–QTOF). Based on observed differences in metabolite profiles, 12 unknown target metabolites were used to generate a predictive model that identified emphysema patients with 90% sensitivity [48]. A recent gas chromatography-mass spectrometry (GC-MS) based plasma metabolite profiling was applied to effectively predict the presence of cancer in 10 out of 10 lung cancer patients, 8 out of 8 non-smokers, 8 out of 9 COPD smokers and 5 out of 10 healthy smokers, based on 32 differentially-expressed metabolites across the 4 patient groups [47]. Of these 32 putative metabolite biomarkers, 21 were of unknown molecular identity, but were defined by their accurate mass and chromatographic retention times.

In attempt to uncover biomarkers for early-stage COPD, we performed untargeted LC/MS profiling of a cohort of 118 human subjects comprised of healthy smokers, COPD smokers and healthy non-smokers, all with well-characterized clinical lung function parameters. The COPD smokers used in this study were classified as mild, belonging to GOLD I/II disease severity groups [3]. We surveyed relative levels of 1,181 molecular ions that could be measured in 95% of patient serum samples to generate a COPD prediction model with 87.8% sensitivity and 86.5% specificity. Efficacy of the model for predicting COPD was found to be 80% in a follow-on study of a small independent cohort. Differentially-upregulated molecules in COPD smokers vs. healthy smokers included a modified form of fibrinogen peptide B along with 3 additional peptides. To our knowledge, this is the first discovery of significantly elevated (greater than 2-fold) serum peptides in early-stage COPD patients with predictive potential. These results point to an intriguing linkage between thrombosis, cell signaling aberrations and early onset of COPD.
**Materials and Methods**

**Human patient cohort**

Serum samples from an initial cohort of 118 human subjects were categorized into 3 groups: healthy nonsmokers (n = 37), healthy smokers (n = 40) and COPD smokers (n = 41). These samples were used in attempt to identify small molecule biomarkers (50–1000 Da) that significantly distinguish COPD smokers from healthy smokers and nonsmokers. The validity of inferred serum COPD biomarkers was further assessed in an independent study cohort comprising healthy nonsmokers (n = 10), healthy smokers (n = 9), COPD smokers (n = 10) and COPD subjects who had quit smoking for > 3 months (n = 19). Serum samples were obtained in the morning following overnight fasting. All subjects were phenotyped with regard to medical history, physical exam, routine blood and urine tests, urine nicotine/cotinine levels, lung function (forced vital capacity (FVC), forced expiratory volume in 1 sec (FEV1), FEV1/FVC, total lung capacity and diffusing capacity and chest high-resolution tomography (HRCT).

Serum samples from 3 smokers (2 males and 1 female) were not acquired for LC/MS negative ion mode due to a sample handling error (See LC/MS methods for description). All COPD subjects were categorized as GOLD I and II in terms of severity, according to post-bronchodilator lung function defined by the GOLD classification [3].

**Reagents**

LC-MS grade acetonitrile (ACN), isopropanol (IPA) and methanol (MeOH) were purchased from Fischer Scientific. High purity deionized water (ddH2O) was filtered from Millipore (18 OMG). OmniTrace glacial acetic acid and ammonium hydroxide were obtained from EMD Chemicals. Ammonium acetate and all other chemicals and standards were obtained from Sigma Aldrich in the best available grade.

**Serum metabolite extraction and metabolomic data acquisition**

Serum metabolites were extracted by addition to 1 part serum to 20 parts (vol:vol) 70% acetonitrile in ddH2O containing 0.2% ammonium hydroxide. The mixture was briefly vortexed and then centrifuged for 5 min at 16,000 × g to pellet precipitated proteins. An aliquot of the resulting extract (3 μl) was subjected to untargeted metabolite profiling using LC/MS and both positive and negative ion monitoring. The sequence of analyzed samples was randomized to eliminate sample order bias of results. Additionally, to minimize bias that may be introduced by drifting of chromatographic retention times and detected mass measurements with large sample runs, a pooled extract from all serum samples was prepared, stored in single-thaw aliquots, and used as a quality control to correct for potential day-to-day and batch-to-batch LC/MS data drift. One quality control sample was analyzed every 6 study samples and flanking quality control results were used to normalize the group of intervening samples.

**LC/MS metabolomics platform for untargeted metabolite profiling**

Serum extracts were analyzed by LC/MS as described previously [59, 60] using a platform comprised of an Agilent Model 1200 liquid chromatography system coupled to an Agilent 6230 time-of-flight MS analyzer. Chromatography of metabolites was performed using aqueous normal phase (ANP) gradient separation, on a Diamond Hydride column (Microsolv). Mobile phases consisted of: (A) 50% isopropanol, containing 0.025% acetic acid, and (B) 90% acetonitrile containing 5 mM ammonium acetate. To eliminate the interference of metal ions on the chromatographic peak integrity and electrospray ionization, EDTA was added to the mobile phase at a final concentration of 6 μM. The following gradient was applied: 0–1.0 min, 99%B;
1.0–15.0 min, to 20%; 15.0 to 29.0, 0%; 29.1 to 37 min, 99%. Raw data were analyzed using MassHunter Profinder 6.0 and MassProfiler Professional 13.0 software package (Agilent technologies). Unpaired t-tests (p<0.05) with Bonferroni correction for multiple group comparisons and ANOVA were used to determine significant differences between groups.

Differentially expressed metabolite identification

To ascertain the identities of differentially expressed metabolites (P<0.05) among COPD smokers, healthy smokers and healthy non-smokers, LC/MS data were searched against an in-house annotated METLIN Personal Metabolite Database (Agilent Technologies), based on accurate monoisotopic neutral masses (<5 ppm) and chromatographic retention times. A molecular formula generator (MFG) algorithm in MPP was used to generate and score empirical molecular formulae based on a weighted consideration of monoisotopic mass accuracy, isotope abundance ratios, and spacing between isotope peaks. A tentative compound ID was assigned when METLIN and MFG scores concurred for a given candidate molecule. Tentatively assigned molecules were verified based on a match of LC retention times and/or MS/MS fragmentation spectra to that of pure molecule standards in our progressively growing in-house database.

Results

Clinical characteristics of human subjects

Clinical characteristics of the initial study group are summarized in Table 1. A total of 118 serum samples were collected from 92 males and 26 females. The nonsmoker group comprised a balanced number of male and female patients, whereas the healthy smoker and COPD smoker groups were dominated by male subjects. Baseline parameters were similar in BMI and...

Table 1. Human subjects and associated clinical parameters.

|                        | Non-smokers | Healthy smokers | COPD smokers |
|------------------------|-------------|-----------------|--------------|
| Number of subjects     | 37          | 40              | 41           |
| Gender                 | 19M, 18F    | 35M, 5F         | 38M, 3F      |
| Ethnicity              | 14 His, 13 Afr, 10 Eur | 14 His, 11 Afr, 5 Eur | 9 His, 23 Afr, 8 Eur, 1 mixed |
| Packs per year         | n/a         | 21.5 ± 11.3     | 30.6 ± 1.7   |
| Packs per day          | n/a         | 0.9 ± 0.6       | 0.8 ± 0.5    |
| Age of initiation      | n/a         | 15.2 ± 2.9      | 16.7 ± 3.3   |
| Age                    | 39.5 ± 13.0 | 41.8 ± 10.1     | 53.2 ± 7.7   |
| BMI                    | 26.6 ± 5.0  | 26.9 ± 4.9      | 25.6 ± 3.6   |
| FEV1%                  | 104.0 ± 11.5| 105.5 ± 11.0    | 77.7 ± 18.9  |
| FVC%                   | 108.0 ± 11.3| 110.5 ± 11.0    | 106.0 ± 16.4 |
| FEV1/FVC%              | 80.0 ± 5.7  | 77.9 ± 4.3      | 58.5 ± 7.6   |
| TLC                    | 97.7 ± 15.7 | 93.8 ± 9.2      | 101.6 ±14.5  |
| DLCO                   | 90.4 ± 11.4 | 87.2 ± 8.5      | 68.5 ±14.3   |
| COHb                   | 1.6 ± 0.8   | 2.9 ± 1.2       | 3.3 ± 1.2    |
| Urine cotinine         | n/a         | 1687.0 ±1073.4  | 1619.5 ±885.1|

1All values were presented as mean ± standard deviation

M = Male, F = Female; His: Hispanic ethnicity, Afr: African ethnicity; Eur: European ethnicity; FEV1: forced expiratory value in 1 second; FVC: functional vital capacity; TLC: total lung capacity; DLCO: diffusing capacity of the lung for carbon monoxide. COHb: carboxylhemoglobin. All lung function parameters are presented as % predicted except for FEV1/FVC which is expressed as % observed. N/A = not applicable.

doi:10.1371/journal.pone.0143937.t001
ethnicity for all groups. Both healthy smokers and COPD smokers had a comparable cigarette consumption rate and smoking history. COPD subjects on average were older than healthy smokers and non-smokers.

Urine cotinine, the nicotine metabolite, and blood COHb were at comparable levels for healthy smokers and COPD smokers and, as expected, low or undetected in non-smokers. Compared to healthy non-smokers and healthy smokers, COPD smokers had significantly decreased DLCO and FEV1/FVC ratio, the basis for clinical diagnosis of COPD. DLCO and FEV1/FVC were significantly correlated with each other (Pearson correlation coefficient \( R = 0.62, P < 6.3 \times 10^{-14} \)) and readily discriminated healthy smokers from COPD smokers. Total lung capacity showed no difference between COPD smokers and nonsmokers. All COPD smokers were classified as belonging to the least severe, GOLD I and GOLD II disease groups. Given that healthy smokers and COPD smokers had an indistinguishable cigarette exposure and smoking history, comparison of plasma metabolites between these groups should allow for discovery of biomarkers with potential to distinguish the groups and predict health outcomes.

**Serum metabolite profile of non-smokers, healthy smokers and COPD smokers**

COPD is routinely diagnosed based on clinical parameters related to lung airway function (e.g. FEV1/FVC%). However, such clinical parameters do not directly correlate with the overall health status of patients. Moreover, measurements of lung function provide little prognostic information regarding anticipated disease severity. In contrast, circulating serum metabolites offer a potential window into systemic physiology/pathophysiology and the possibility of informative and predictive COPD biomarkers. To compensate for the limited prognostic potential of clinical lung parameters, we sought to identify serum metabolites that may inform on COPD health status and outcomes.

Applying an untargeted LC/MS-based metabolomics platform that uses aqueous normal phase chromatographic separation coupled to time-of-flight MS, we successfully quantified the relative levels of 586 positive ions and 635 negative ions in 95% of all serum samples studied (including quality control samples). Combining positive and negative ions, after excluding duplicate features measured in both MS detection modes, 1,181 total aligned molecular features in the range of 50–1,000 Da were quantified in all serum samples (Fig 1A). To account for day-to-day and batch-to-batch LC/MS instrument drift, metabolite stability and other experimental factors that can contribute to systematic error, we normalized individual serum metabolite measurements from all subjects based on levels quantified in flanking quality control samples. This normalization procedure enabled the comparative analysis of data from a relatively large number of clinical samples, quantified on different occasions.

Unsupervised hierarchical cluster analysis (HCA) revealed a clear and reproducible pattern of within-group metabolite expression similarities and between-group differences (Fig 1B). A Venn diagram, depicted in Fig 1C, contrasts the number of differentially expressed metabolites and shared metabolite changes among healthy non-smokers, healthy smokers and COPD smokers. Of 1,181 features quantified in 95% of samples, 62 metabolites were found to be significantly different in abundance (\( P < 0.05 \)) between healthy smokers and COPD smokers. Of these, 17 metabolites were differentially-expressed (up or down) in COPD smokers compared to both healthy smokers and healthy non-smokers, but also showed no difference between healthy smokers and healthy non-smokers (i.e., metabolites that distinguish COPD smokers from both healthy smokers and healthy non-smokers). Regardless of whether smokers were healthy or had COPD, smoking itself was associated with 107 serum metabolite changes, relative to non-smokers. Among these smoking-associated serum metabolites, 20 were unknowns
Fig 1. Untargeted metabolite profiling identifies differentially-expressed serum metabolites among COPD smokers, healthy smokers, and non-smokers ($P < 0.05$).

(A) A total of 1,181 aligned molecular features detected as positive and negative ions were quantified in all 115 serum samples by untargeted molecular feature extraction. (B) Heat map from hierarchical clustering analysis, showing 314 differentially-expressed metabolites among COPD smokers, healthy smokers and non-smokers. The relative level of Metabolite Profiling of COPD

PLOS ONE | DOI:10.1371/journal.pone.0143937 December 16, 2015 6/2 0
that were elevated by 1.5-fold or greater in both healthy and COPD smokers, compared to non-smokers (P < 0.05, Table 2). These 20 unknowns were defined by their accurate neutral mass and chromatographic retention time on ANP chromatographic matrix. As expected, the abundant nicotine metabolites, cotinine and hydroxy-cotinine, were dramatically increased in serum from both healthy and COPD smoker groups. Additionally, smoking was associated with altered levels of serum phospholipids and bile acids, but the extent of these changes were undistinguishable between healthy smokers and COPD smokers.

COPD-specific serum metabolite changes

The goal of untargeted metabolite profiling in this study was to discover serum metabolites of known and/or unknown molecular identities that distinguish the population of COPD smokers. Such biomarkers should meet the criteria of discriminating between COPD smokers from healthy smokers, but also exhibit no significant differences between healthy smokers and healthy nonsmokers. Table 3 summarizes the list of metabolites meeting these criteria.

Table 2. Differential metabolites between COPD smoker and healthy smoker compared to non-smokers.

| METABOLITE                              | Mass   | RT      | P   | FC   | P   | FC   | P   | FC   |
|-----------------------------------------|--------|---------|-----|------|-----|------|-----|------|
|                                        |        |         | S vs NS |       | COPD vs NS | COPD vs NS | COPD vs S | COPD vs S |
| Cotinine                                | 176.093| 3.67    | 1.54E-14 | 23.27 | 5.84E-18 | 24.09 | 7.81E-01 | 1.04 |
| 3-Hydroxycotinine                       | 192.092| 3.45    | 1.99E-13 | 4.85  | 4.23E-13 | 5.51  | 2.97E-01 | 1.14 |
| Unknown 1                               | 742.23 | 0.71    | 1.36E-03 | 3.36  | 2.84E-02 | 2.5   | 3.54E-01 | 0.74 |
| Quinic acid                             | 192.061| 4.41    | 6.98E-03 | 2.60  | 5.33E-04 | 3.77  | 1.72E-01 | 1.45 |
| lysoPi(20:0)                            | 628.36 | 4.47    | 3.85E-02 | 2.19  | 5.14E-02 | 2.23  | 9.62E-01 | 1.02 |
| PI(32:2)                                | 806.506| 1.8     | 1.40E-02 | 2.11  | 8.52E-03 | 1.78  | 4.83E-01 | 0.84 |
| Glycochenodeoxycholic acid 3-glucuronide| 625.345| 6.53    | 1.81E-03 | 2.00  | 7.45E-02 | 2.23  | 7.49E-01 | 1.11 |
| PI(32:1)                                | 808.511| 1.84    | 6.57E-03 | 1.89  | 1.90E-02 | 1.47  | 2.27E-01 | 0.78 |
| 5-Acetylamino-6-formylamino-3-methyluracil| 226.072| 0.69    | 3.85E-03 | 1.89  | 2.13E-02 | 1.42  | 1.34E-01 | 0.75 |
| Unknown2                                | 600.451| 1.02    | 1.39E-02 | 1.83  | 4.00E-03 | 1.88  | 9.00E-01 | 1.03 |
| PI(32:0)                                | 810.516| 1.84    | 2.73E-03 | 1.81  | 1.33E-02 | 1.47  | 2.30E-01 | 0.81 |
| Glycochenodeoxycholate-3-sulfate        | 529.27 | 1.61    | 1.63E-02 | 1.65  | 7.96E-02 | 1.7   | 9.09E-01 | 1.03 |
| PE(35:1)                                | 731.546| 7.64    | 7.91E-03 | 1.65  | 7.27E-03 | 1.46  | 4.52E-01 | 0.88 |
| Unknown3                                | 200.014| 0.72    | 3.04E-02 | 1.61  | 4.91E-03 | 2.52  | 7.60E-02 | 1.57 |
| 1α,25-dihydroxy-23-thiavin D3           | 434.296| 1.77    | 1.53E-03 | 1.54  | 1.93E-03 | 1.52  | 9.34E-01 | 0.99 |
| PI(40:4)                                | 914.583| 1.84    | 5.95E-04 | 1.54  | 2.38E-04 | 1.5   | 7.92E-01 | 0.97 |
| Unknown                                 | 602.468| 1.03    | 3.24E-02 | 1.52  | 1.75E-03 | 1.63  | 6.95E-01 | 1.07 |
| 6-methyltetrahydropterin                | 181.098| 1.19    | 2.58E-05 | 1.51  | 2.85E-07 | 1.8   | 3.19E-02 | 1.19 |
| PE(33:1)                                | 703.516| 7.71    | 2.78E-02 | 1.51  | 1.90E-02 | 1.43  | 7.24E-01 | 0.94 |
| PI(34:1)                                | 836.539| 1.85    | 2.67E-03 | 1.51  | 1.68E-02 | 1.3   | 2.42E-01 | 0.86 |

\(^{1}\text{RT = retention time}\)

\(P = p\) value; \(S = \text{smokers, NS = nonsmoker, FC = fold-change}\)

doi:10.1371/journal.pone.0143937.t002
Table 3. Differential metabolites between COPD smokers compared to healthy smokers.

| METABOLITEM                  | Mass        | RT    | P COPD vs S | FC COPD vs S | P COPD vs NS | FC COPD vs NS | P S vs NS | FC S vs NS |
|------------------------------|-------------|-------|-------------|--------------|--------------|--------------|-----------|------------|
| Fibrinogen peptide B         | 1395.559    | 8.89  | 5.56E-03    | 2.41         | 7.58E-03     | 2.38         | 9.60E-01 | 0.99       |
| Peptide 1                    | 1464.654    | 10.44 | 1.14E-02    | 3.28         | 1.02E-02     | 3.74         | 6.17E-01 | 1.14       |
| Peptide 2                    | 1308.547    | 9.51  | 4.75E-03    | 2.44         | 8.47E-03     | 2.23         | 7.29E-01 | 0.91       |
| Peptide 3                    | 1049.464    | 9.38  | 9.04E-04    | 2.51         | 1.03E-02     | 1.89         | 2.40E-01 | 0.75       |
| Peptide 4                    | 859.3717    | 8.68  | 1.12E-02    | 2.09         | 6.00E-02     | 1.65         | 2.47E-01 | 0.79       |
| 1,7 Dimethyluric acid        | 196.058     | 2.17  | 3.72E-02    | 1.57         | 9.34E-03     | 1.8          | 4.96E-01 | 1.14       |
| Myoinositol                  | 180.062     | 5.61  | 3.69E-02    | 1.33         | 2.93E-04     | 1.64         | 9.87E-02 | 1.23       |
| PI(40:7)                     | 908.542     | 1.84  | 4.20E-03    | 1.24         | 1.32E-03     | 1.35         | 3.92E-01 | 1.09       |
| L-Cysteinesulfonic acid      | 200.976     | 1.87  | 2.33E-02    | 1.26         | 2.46E-02     | 1.23         | 8.04E-01 | 0.97       |
| *Creatinine                  | 113.056     | 7.52  | 3.93E-02    | 1.15         | 7.08E-02     | 1.14         | 9.03E-01 | 0.99       |
| N-Methylnicotinate           | 137.049     | 10.89 | 5.70E-02    | 1.72         | 6.31E-03     | 2.51         | 1.72E-01 | 1.46       |
| * Unknown 1                  | 863.402     | 8.7   | 6.54E-03    | 1.94         | 5.00E-02     | 1.58         | 2.62E-01 | 0.82       |
| Unknown 2                    | 627.55      | 1.85  | 1.72E-02    | 1.27         | 2.83E-04     | 1.55         | 6.68E-02 | 1.22       |
| Unknown 3                    | 234.085     | 9.61  | 1.53E-03    | 0.9          | 6.77E-03     | 0.87         | 4.68E-01 | 0.97       |
| Unknown 5                    | 935.513     | 7.4   | 1.14E-02    | 0.81         | 1.55E-02     | 0.84         | 5.68E-01 | 0.96       |
| Unknown 6                    | 592.47      | 1.61  | 8.60E-03    | 0.63         | 4.28E-02     | 0.72         | 4.65E-01 | 1.14       |
| Unknown 7                    | 922.497     | 1.83  | 4.73E-02    | 1.16         | 1.09E-02     | 1.27         | 3.88E-01 | 1.09       |
| Unknown 8                    | 482.105     | 0.75  | 1.90E-02    | 1.38         | 2.31E-02     | 1.39         | 9.48E-01 | 1.01       |
| Unknown 9                    | 834.596     | 7.19  | 2.43E-04    | 1.43         | 8.84E-02     | 1.17         | 7.67E-02 | 0.82       |
| Fumarate                     | 116.011     | 6.96  | 1.00E-03    | 0.72         | 3.50E-01     | 0.94         | 1.00E-02 | 1.3        |
| 3-hydroxyvalerate            | 118.061     | 1.7   | 3.40E-03    | 0.5          | 4.40E-01     | 0.89         | 1.00E-02 | 1.86       |
| Unknown 10                   | 72.056      | 1.71  | 4.32E-03    | 0.59         | 8.70E-01     | 0.98         | 9.47E-03 | 1.66       |
| Unknown 11                   | 496.306     | 1.05  | 5.67E-03    | 0.61         | 1.27E-01     | 0.42         | 4.59E-01 | 0.70       |
| Unknown 12                   | 576.476     | 1.52  | 1.07E-02    | 0.68         | 2.75E-01     | 0.88         | 9.43E-02 | 1.28       |
| Unknown 13                   | 736.464     | 1.02  | 1.05E-03    | 0.43         | 1.58E-01     | 0.21         | 3.82E-01 | 0.48       |
| Unknown 14                   | 290.004     | 9.28  | 5.11E-02    | 1.25         | 3.10E-01     | 1.13         | 4.31E-01 | 0.90       |
| Unknown 15                   | 225.068     | 0.68  | 5.05E-02    | 0.66         | 2.24E-01     | 1.25         | 4.59E-03 | 1.91       |
| Unknown 16                   | 660.262     | 0.78  | 1.00E-02    | 0.68         | 2.74E-01     | 0.85         | 1.57E-01 | 1.25       |
| *2-Methylhippuric acid       | 193.065     | 4.36  | 1.02E-01    | 1.91         | 1.54E-02     | 3.8          | 1.14E-01 | 1.99       |
| *5-Acetylamino-6-amino-3-methyluracil | 198.072 | 3.57 | 6.19E-02 | 1.49 | 3.97E-03 | 1.92 | 2.45E-01 | 1.29 |

1Underlined metabolites were used for generating prediction model.
* denotes metabolites showing significant correlation with mFBP (Pearson correlation R ≥ 0.34, P ≤ 2.0e-4)

RT = retention; P = p value; FC = fold-change; S = smoker, NS = nonsmokers

doi:10.1371/journal.pone.0143937.t003

Notably, five peptides were uniquely increased in serum from COPD smokers compared to the other groups. These peptides were all detected by positive ion MS as doubly-charged ions. Fragmentation of the unknown peptides by QTOF revealed that one of these was a modified version of the 14 amino acid fibrinogen peptide B (FPB; EGVNDNEEGFFSAR) (Fig 2), wherein the N-terminal glutamate was observed as pyroglutamate and the C-terminal arginine was deleted. Serum products of fibrinogen turnover have been reported to be involved in inflammation and wound healing [61], and elevated plasma fibrinogen has previously been associated with reduced pulmonary function and increased risk of COPD [8, 9]. To our knowledge, this is the first report of N-terminal modified and C-terminal truncated fibrinogen peptide B (mFBP) in
early-stage COPD smokers. The amino acid sequences of the other four peptides were not solved, but their relative levels were significantly and positively correlated with each other, and with modified fibrinogen peptide B (Pearson coefficient $R^2 = 0.68$ and $P < 9.3 \times 10^{-18}$; Fig 3).

In addition to peptides, serum myoinositol, dimethyluric acid and N-methylnicotinate were significantly increased in COPD smokers, as compared with both healthy smokers and non-smokers. Serum cysteinsulfonic acid glycerophosphoinositol, phosphatidylinositol (40:7) and creatinine were also modestly elevated in COPD smokers. Two metabolites, 2-methylhippuric acid and 5-acetylamino-6-amino-3-methyluracil, were markedly increased in COPD smokers compared to healthy non-smokers, and also showed a trend of increase in comparison with healthy smokers, with $P$ values approaching significance. In contrast, several hydrophobic unknowns (with chromatographic retention time consistent with fatty acids and lipids) were mildly decreased in COPD. Notably, the COPD cohort in this study had relatively mild GOLD I and II classified disease, and non-peptide serum metabolite changes were found to be modest compared to healthy smokers, but significant. Except for four metabolites that showed a significant correlation with mFBP (denoted by asterisks in Table 3), other non-peptide metabolites were not significantly correlated with mFBP or other observed unsequenced peptides (not shown). Unknown1 (mass 863.40 Da at 8.8 min retention time), creatinine and 2-methylhippurate showed the most significant correlation with mFBP ($r = 0.77$, $P < 3.0 \times 10^{-23}$; $r = 0.47$, $P < 1.3 \times 10^{-7}$; and $r = 0.47$, $P < 2.5 \times 10^{-7}$, respectively). This raises the possibility that COPD-associated changes in non-peptide and peptide metabolites, may have distinct mechanistic implications for COPD pathophysiology.

Fig 2. MS/MS fragmentation of a doubly-charged ion ([M+2H] = 697.97 Da) reveals the sequence of peptide as pyroEGVNDNEEGFFSA. Fragments derived from ion fragmentation at 30 EV match the amino acid sequence of fibrinogen peptide B with truncated C-terminal arginine and N-terminal amino acid modified as pyroglutamate.

doi:10.1371/journal.pone.0143937.g002

Des-Asp-FPB: pyroEGVNDNEEGFFSA
Correlation of serum metabolites with clinical parameters

The spirometric parameter FEV1/FVC is the classic hallmark for defining and characterizing the severity of COPD, though it does not always correlate well with health status or disease symptoms. Urine cotinine and hydroxycotinine reflect the extent of cigarette smoking, but do not correlate with the severity of lung function deficits. In order to find a link between lung dysfunction and altered levels of serum metabolites elicited by smoking, we sought to correlate the relative levels of serum metabolites that distinguish COPD smokers from both healthy smokers and non-smokers with the clinical lung function parameters FEV1/FVC, DLCO, TLC and COHb. **Table 4** lists those metabolites showing a significant Pearson correlation coefficient ($P<0.05$) with at least one of these lung function parameters. Interestingly, five non-peptide metabolites (N-methylnicotinate, myoinositol, dimethylurate, methylhippurate and 5-acetylamino-6-amino-3-methyluracil) were observed to correlate with all four lung function parameters ($P<0.05$). In contrast, mFBP and all other non-sequenced peptides selectively and strongly correlate with FEV1/FVC and DLCO ($P<0.0003$), weakly correlated with COHb, and demonstrated no correlation with TLC. Several other non-peptide metabolites strongly correlated.

![Correlation graphs](image-url)
with FEV1/FVC, but exhibited no correlation with COHb and TLC. Serum creatinine and cysteinesulfonic acid showed no significant correlation with any of the lung parameters. Overall, serum metabolites demonstrated a heterogeneous correlation with lung function tests.

Table 4. Correlation of serum metabolites with clinical lung parameters (Pearson correlation).

| Metabolite | %FEV1/FVC | DLCO | TLC | COHb |
|------------|-----------|------|-----|------|
|            | Pearson R | P value | Pearson R | P value | Pearson R | P value | Pearson R | P value |
| N-Methylnicotinate | -0.3934 | 1.05E-05 | -0.185 | 0.045 | 0.3571 | 7.20E-05 | 0.3293 | 0.0003 |
| Myoinositol | -0.4385 | 9.51E-07 | -0.2495 | 0.0071 | 0.3552 | 9.81E-05 | 0.338 | 0.0002 |
| Dimethylurate | -0.3164 | 0.0006 | -0.2609 | 0.0049 | 0.2054 | 0.028 | 0.2448 | 0.0087 |
| 2-Methylhippurate | -0.3524 | 0.0001 | -0.3738 | 3.87E-05 | 0.2417 | 0.0093 | 0.2684 | 0.0039 |
| 5-Acetylamino-6-amino-3-methyluracil | -0.3601 | 7.72E-05 | -0.3279 | 0.0003 | 0.2534 | 0.0063 | 0.3144 | 0.0007 |
| 863.40@8.7 | -0.3636 | 7.00E-05 | -0.2891 | 0.0018 | 0.004137 | NS | 0.1252 | NS |
| 627.55@1.85 | -0.2415 | 0.0084 | -0.2297 | 0.012 | -0.004 | NS | 0.211 | 0.02 |
| 592.47@1.67 | 0.2821 | 0.0023 | -0.1535 | NS | 0.009827 | NS | 0.02193 | NS |
| 284.061@8.88 | 0.239 | 0.0091 | 0.2421 | 0.0083 | -0.05 | NS | -0.11 | NS |
| 234.085@9.61 | 0.2473 | 0.0069 | 0.1205 | NS | -0.05 | NS | -0.06 | NS |
| Fibrinogen peptide B | -0.3016 | 0.0009 | -0.3659 | 4.61E-05 | -0.00968 | NS | 0.2393 | 0.0094 |
| Peptide 1464.65@10.44 | -0.326 | 0.0003 | -0.5185 | 1.81E-09 | 0.1385 | NS | 0.2422 | 0.0085 |
| Peptide 859.371@8.68 | -0.3763 | 4.00E-05 | -0.3096 | 0.0003 | 0.003102 | NS | 0.1267 | NS |
| Peptide 1308.547@9.51 | -0.3794 | 2.89E-05 | -0.433 | 1.34E-06 | 0.07092 | NS | 0.1768 | 0.0558 |
| Peptide 1049.464@9.38 | -0.4115 | 7.23E-06 | -0.3942 | 1.86E-05 | 0.04195 | NS | 0.1725 | 0.075 |

doi:10.1371/journal.pone.0143937.t004

Serum metabolite prediction model for COPD

A serum metabolite-based prediction model for early early-stage COPD may suggest pathophysiological mechanisms and have predictive power beyond that offered by lung function parameters alone. Accordingly, we sought to identify a predictive serum metabolite signature for GOLD stage I/II COPD. Because non-smokers with no prior exposure to cigarette smoking and no detectable nicotine metabolites are unlikely to develop COPD, non-smokers were excluded from COPD model generation. Considering 23 metabolites that distinguished COPD smokers from healthy smokers (underlined metabolites in Table 3), we conducted a partial least square discriminant analysis (PLS-DA) to classify the COPD smokers and healthy smokers, employing Agilent MassProfiler Professional 13.0 software. The PLS-DA score plot shows a marked separation of COPD smokers from healthy smokers (Fig 4A). The sensitivity of the constructed model was calculated from the ratio of predicted true COPD smokers vs. total COPD smokers, whereas specificity of the model was calculated as the ratio of predicted true healthy smokers to the total number of healthy smokers. Applying this quantitative approach, the classification sensitivity was found to be 36 out of 41 COPD smokers (87.8%), and the classification specificity was 32 out of 37 healthy smokers (86.5%). Based on these findings, the overall accuracy of classification was 87.2%. The receiver operator characteristics (ROC) were obtained by plotting the sensitivity against specificity at different discriminant thresholds. The area under the ROC, commonly used as a diagnostic statistic for PLS-DA models, was 0.87 (Fig 4B). ROC curves were generated using ROC Curve Explorer and Tester (ROCCET, http://www.roccet.ca/ROCCET/), using the same set of data for which Monte Carlo Cross Validation (MCCV) was applied via balanced subsampling. In each MCCV analysis, two thirds of the samples were used to evaluate the feature importance. The 23 differentially expressed COPD serum metabolites were then used to build classification models that were validated based on
Fig 4. Characterization of a PLS-DA prediction model for identification COPD smokers, based on 23 serum metabolites. (A) Three-dimensional score plot of PLS-DA classification model showing the partial separation of COPD smokers from healthy smokers. (B) Diagnostic statistics for the presented PLS-DA model, as area under the receiver operator characteristics curve (AUC). The AUC was 0.87 with a 95% confidence interval of 0.761–0.957 for the constructed model. (C) The location of original between-sum
1/3 of the samples left out. The procedure was repeated multiple times to calculate the performance and confidence interval for the model.

PLS-DA is prone to data over-fitting, and therefore the generated models need to be validated by assessing whether the observed separation is indeed statistically significant, or due to random noise. To eliminate the random chance that the constructed model has discriminating power for COPD smokers vs. healthy smokers, a permutation test was performed using non-proprietary MetaboAnalyst 3.0 software, involving 2,000 permuted class labels—this tested the assumption that there is no difference between COPD smokers and healthy smoker groups. In each permutation, a PLS-DA model was built between the data (X) and the permuted class labels (Y), using the optimal number of components determined by cross-validation of the model based on the original class assignment. The ratio of between-sum squares and the within-sum squares (B/W-ratio) for the prediction of each model was calculated. Fig 4C shows the location of original B/W ratio, relative to the distribution histogram of 2,000 permuted B/W ratios. The B/W ratio of the original classification assignment (COPD smokers vs. healthy smokers) was further to the right of the distribution, with a permutation P value less than 5.0 x 10^-4, affirming the statistical significance and validity of the PLS-DA model.

Validation of the COPD classification model

We sought to test the efficacy of the 23 metabolite signature for prediction of early-stage COPD in an independent group of subjects. As shown in S1 Table, applying the 23 serum metabolite model to an independent group of 10 early-stage COPD patients correctly classified these subjects as having COPD in 80% of cases. Further, in a cohort of 19 COPD patients who quit smoking for ≥ 3 months, this classification algorithm recognized the COPD metabotype in 14/19 subjects in accord with their active COPD.

Discussion

In attempt to uncover biomarkers that identify early-stage (GOLD I/II) COPD, we performed untargeted LC/MS profiling in a cohort of 118 healthy smokers, COPD smokers and non-smokers with well-characterized clinical lung function parameters. We report here the identity of circulating serum metabolites as potential COPD biomarkers. To our knowledge, this is the first comprehensive untargeted metabolite profiling for serum markers of COPD, comparing non-smokers, healthy smokers and early-stage COPD smokers. This analysis identified a group of 23 non-peptide and peptide metabolites, some of which were not directly correlated with any lung function parameters, potentially providing pathophysiological information over and above that obtained from clinical testing. Efficacy of this putative signature for early-stage COPD was provided by an independent validation cohort in which COPD was predicted with 80% success.

One biomarker identified in serum distinguishing COPD smokers from smokers was a modified form of the fibrinogen-derived peptide, FPB. Fibrinogen is an acute phase plasma protein that has emerged as a promising biomarker in COPD [8, 9, 62, 63]. Elevated levels of plasma fibrinogen have been associated with pulmonary dysfunction, coronary heart disease [63] and hospitalization of COPD patients [9]. In blood, thrombin converts fibrinogen to fibrin
in two sequential steps [64], ultimately resulting in equimolar quantities of FPB and fibrin II. Fibrin II is a mediator of thrombosis, polymerizing together with platelets it forms a hemostatic plug or clot over wound sites [65]. The 14-amino acid FPB is susceptible to cleavage by carboxypeptidase in blood, where removal of the C-terminal arginine yields des-arginine FPB. Therefore, measurement of des-arginine FPB indirectly signifies in vivo fibrin II production. Fibrin clot propensity was previously found to be altered in patients with COPD [66]. In accord with this prior finding [66]; our untargeted metabolite profiling revealed that N-terminally modified des-arginine FPB metabolite (pyroEGVNDNEEGFFSA) was elevated in the circulating blood of early-stage COPD subjects, as compared to healthy smokers with a similar smoking history and extent of cigarette exposure. Further, we demonstrated a significant positive correlation between the level of mFBP and the lung function parameters FEV1/FVC% and DLCO in all study subjects. This elevation in mFBP levels suggests that coagulation and thrombogenesis may play a role in COPD smokers. Indeed, quantitative exposure to passive smoke has been shown to positively correlate with blood coagulation activity [67]. The association between acute inflammation, endothelial activation and clotting initiation has been demonstrated in COPD exacerbations [68]. In addition to mFBP, three other unknown peptides were increased in COPD smokers only. Based on the significant correlation with each other and with mFBP, we postulate that these peptides may also belong to the fibrinogen family and/or the thrombotic cascade.

Despite a significantly increased level of circulating mFBP and other peptides in COPD patient serum, the presence of peptides alone did not possess predictive power to accurately identify early stage COPD smokers (AUC ≈ 0.75, not shown). Interestingly, the 4 observed peptide biomarkers shared a negative correlation with the lung function parameters FEV1/FVC% and DLCO, but not with the lung parameters TLC and COHb. In contrast, non-peptide small molecule serum metabolites, including myoinositol, dimethylurate, N-methylnicotinate, and 5-acetylamino-6-amino-3-methyluracil were all significantly correlated with each of the 4 lung function parameters obtained in our patient cohort. Among the non-peptide metabolites, myoinositol evidenced the most significant correlation with clinical parameters. Myoinositol is a cyclic sugar alcohol that functions in glycerophospholipid metabolism and inositol phosphate metabolism, also serving as an osmolyte. Moreover, inositol phosphoglycans comprise a major family of intracellular signaling molecules, including the mediation of insulin action [69]. Furthermore, myoinositol has been used as chemoprevention drug in clinical trials, acting to inhibit Akt and extracellular signal-regulated kinase (ERK) in bronchial lesions from heavy smokers [70]. In vitro studies have shown that myoinositol decreases endogenous and tobacco carcinogen-induced activation of Akt and ERK in immortalized human bronchial epithelial cells [70]. In COPD patient’s sera, we observed that both myoinositol and the inositol-derived plasma membrane phospholipid, glycerophosphoinositol [PI (40:7)] was increased compared to healthy smokers and healthy non-smokers, and elevated levels of glycerophosphoinositol lipids were found in healthy smokers compared to healthy non-smokers. These results suggest an altered pattern of phosphatidylinositol metabolism in smokers. Consistent with this observation, smoking-derived toxins have been related to the activation of PI3K signaling pathway [71–73], altering cell growth, proliferation, survival, and motility in COPD smokers. Thus, increased myoinositol in COPD smokers may be the consequence of feedback regulation of activated PI3K. Notably, high serum myoinositol in COPD can suppress the synthesis of phosphatidylglycerol an important surfactant in the alveolar wall which has been show to decrease in COPD and patients with cystic fibrosis [74].

Elevated levels of serum metabolite N-methylnicotinate, 1,7dimethylurate and 5-acetylamino-6-amino-3-methyluracil (AAMU) in COPD subjects were unexpected, but intriguing. These three metabolites are all related to caffeine metabolism.
trigonelline) is a pyridine alkaloid and metabolite of caffeine, as well as a phytoestrogen, in coffee beans [75, 76]. 1,7 dimethylureate is a metabolic product of caffeine, whose synthesis is primarily catalyzed by CYP2A6. AAMU is also a major caffeine metabolite, synthesized by N-acetyltransferase 2. Notably, these urinary caffeine metabolites have been used to assess the enzymatic activities of xanthine oxidase (XO) [77–79] and N-acetyltransferase 2 (NAT2) and cigarette smoking has been shown to induce cytochrome P450-mediated alkaloid metabolism [80]. Taken together, these findings suggest an acceleration of caffeine metabolism in COPD smokers, especially for the downstream caffeine metabolites resulting from activated CYP2A6. This is the first untargeted serum profiling finding that points to a potential upregulation of caffeine metabolism in COPD smokers.

In summary, our untargeted serum metabolite profiling revealed metabolite biomarkers of early-stage COPD that are indicative of thrombosis, altered cell signaling and metabolic changes. Based on 23 serum metabolites, the prediction of COPD amongst a mixed group of both healthy and COPD smokers had an overall 87% accuracy and was found to be 80% correct when predicting COPD in an independent population of COPD smokers. Combined with clinical parameters, the identified serum markers offer the potential to improve sensitivity and specificity for predicting and monitoring COPD prognosis in cigarette smokers.

Supporting Information

S1 Table. Prediction of COPD in subjects with COPD who are either active smokers (COPDact) and who have quit smoking for ≥ 3 months (COPDquit).

(DOCX)

Acknowledgments

We thank C. Hollmann and S. Hyde in the Department of Genetic Medicine for help with the clinical regulatory aspects of these studies. These studies were supported, in part, by NIH R01HL107882, R01HL1189541, R37HL087062 and P20 HL113443. Research reported in this publication was supported in part by the Family Smoking Prevention and Tobacco Control Act. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or the Food and Drug Administration.

Author Contributions

Conceived and designed the experiments: QC RSD SSG RGC. Performed the experiments: QC RSD YM. Analyzed the data: QC YM. Contributed reagents/materials/analysis tools: RGS MS SSG. Wrote the paper: QC SSG RGC.

References

1. Koutokera A, Kostikas K, Nicod LP, Fitting JW. Pulmonary biomarkers in COPD exacerbations: a systematic review. Respiratory research. 2013; 14:111. doi:10.1186/1465-9921-14-111 PMID: 24143945; PubMed Central PMCID: PMC4014989.
2. Qaseem A, Will TJ, Weinberger SE, Hanania NA, Criner G, van der Molen T, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med. 2011; 155(3):179–91. doi:10.7326/0003-4819-155-3-201108020-00008 PMID: 21810710.
3. Vestbo J, Vogelmeier C, Small M, Higgins V. Understanding the GOLD 2011 Strategy as applied to a real-world COPD population. Respiratory medicine. 2014; 108(5):729–36. Epub 2014/03/29. doi: 10.1016/j.rmed.2014.03.002 PMID: 24675239.
4. Lopez-Campos JL, Calero C, Lopez-Ramirez C, Asensio-Cruz MI, Marquez-Martin E, Ortega-Ruiz F. Patient-reported outcomes and considerations in the management of COPD: focus on aclidinium.
5. Westwood M, Bourbeau J, Jones PW, Cerulli A, Capkun-Niggl G, Worthy G. Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review. Respiratory research. 2011; 12:40. Epub 2011/04/12. doi: 10.1186/1465-9921-12-40 PMID: 21477298; PubMed Central PMC:3909353.

6. Rosenberg SR, Kalhan R. Biomarkers in chronic obstructive pulmonary disease. Translational research: the journal of laboratory and clinical medicine. 2012; 159(4):228–37. doi: 10.1016/j.trsl.2012.01.019 PMID: 22424427.

7. Stockley RA. Biomarkers in chronic obstructive pulmonary disease: confusing or useful? International journal of chronic obstructive pulmonary disease. 2014; 9:163–77. doi: 10.2147/COPD.S42362 PMID: 24532968; PubMed Central PMC:3923613.

8. Duvoix A, Dickens J, Haq I, Mannino D, Miller B, Tal-Singer R, et al. Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease. Thorax. 2013; 68(7):670–6. doi: 10.1136/thoraxjnl-2012-201871 PMID: 22744884; PubMed Central PMC:3711372.

9. Dahl M, Tybaerg-Hansen A, Vestbo J, Lange P, Nordestgaard BG. Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine. 2001; 164(6):1008–11. doi: 10.1164/ajccm.164.6.2010067 PMID: 11587967.

10. Schuetz P, Marlowe RJ, Mueller B. The prognostic blood biomarker proadrenomedullin for outcome prediction in patients with chronic obstructive pulmonary disease (COPD): a qualitative clinical review. Clinical chemistry and laboratory medicine: CCLM / FESCC. 2015; 53(4):521–39. doi: 10.1515/cclm-2014-0748 PMID: 25252756.

11. Kurt OK, Tosun M, Kurt EB, Talay F. Pentraxin 3 as a novel biomarker of inflammation in chronic obstructive pulmonary disease. Inflammation. 2015; 38(1):89–93. doi: 10.1007/s10753-014-0010-3 PMID: 25303877.

12. Fruchter O, Yigla M, Kramer MR. D-dimer as a prognostic biomarker for mortality in chronic obstructive pulmonary disease exacerbation. The American journal of the medical sciences. 2015; 349(1):29–35. doi: 10.1097/MAJ.0000000000000332 PMID: 25233043.

13. Barouchos N, Papazafiroupolou A, Iacovidou N, Vrachnis N, Barouchos N, Armeniakou E, et al. Comparison of tumor markers and inflammatory biomarkers in chronic obstructive pulmonary disease (COPD) exacerbations. Scandinavian journal of clinical and laboratory investigation. 2015; 75(2):126–32. doi: 10.3109/00365513.2014.929444 PMID: 25098350.

14. Shaw JG, Vaughan A, Dent AG, O’Hare PE, Goh F, Bowman RV, et al. Biomarkers of progression of chronic obstructive pulmonary disease (COPD). Journal of thoracic disease. 2014; 6(11):1532–47. doi: 10.3978/j.issn.2072-1439.2014.11.33 PMID: 25478195; PubMed Central PMC:4255159.

15. Stockley RA. Biomarkers in chronic obstructive pulmonary disease: confusing or useful? International journal of chronic obstructive pulmonary disease. 2014; 9:163–77. doi: 10.2147/COPD.S42362 PMID: 24532968; PubMed Central PMC:3923613.

16. Johansson SL, Roberts NB, Schlosser A, Andersen CB, Carlsten J, Wulf-Johansson H, et al. Microfibrillar-associated protein 4: a potential biomarker of chronic obstructive pulmonary disease. Respiratory medicine. 2014; 108(9):1336–44. doi: 10.1016/j.rmed.2014.06.003 PMID: 25022422.

17. Heo JS, Park JS, Lee EJ, Kim TH, Jang AS, Park SW, et al. Retinoic acid receptor alpha: One of plasma biomarkers associated with exacerbation of chronic obstructive pulmonary disease. Copd. 2014; 11(2):152–62. doi: 10.3109/15412555.2013.828028 PMID: 24111541.

18. Thomsen M, Ingebrigtsen TS, Marott JL, Dahl M, Lange P, Vestbo J, et al. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. Jama. 2013; 309(22):2353–61. doi: 10.1001/jama.2013.5732 PMID: 23757083.

19. Pastor MD, Nogal A, Molina-Pinelo S, Melendez R, Romero-Romero B, Mediano MD, et al. Identification of oxidative stress related proteins as biomarkers for lung cancer and chronic obstructive pulmonary disease in bronchoalveolar lavage. International journal of molecular sciences. 2013; 14(2):3440–55. doi: 10.3390/ijms14023440 PMID: 23389041; PubMed Central PMC:3588051.

20. MacNee W. Systemic inflammatory biomarkers and co-morbidities of chronic obstructive pulmonary disease. Annals of medicine. 2013; 45(3):291–300. doi: 10.3109/07853890.2012.732703 PMID: 23110517.

21. El-Deek SE, Makhouf HA, Saleem TH, Mandour MA, Mohamed NA. Surfactant protein D, soluble intercellular adhesion molecule-1 and high-sensitivity C-reactive protein as biomarkers of chronic obstructive pulmonary disease. Medical principles and practice: international journal of the Kuwait University, Health Science Centre. 2013; 22(5):469–74. doi: 10.1159/000349934 PMID: 23860258.
22. Dickens JA, Lomas DA. CC-16 as a biomarker in chronic obstructive pulmonary disease. Copd. 2012; 9(5):574–5. doi: 10.3109/15412555.2012.718926 PMID: 23030587.

23. Bowler RP. Surfactant protein D as a biomarker for chronic obstructive pulmonary disease. Copd. 2012; 9(6):651–3. doi: 10.3109/15412555.2012.736317 PMID: 23244171.

24. Verrills NM, Irwin JA, He XY, Wood LG, Powell H, Simpson JL, et al. Identification of novel diagnostic biomarkers for asthma and chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine. 2011; 183(12):1633–43. doi: 10.1164/rccm.201010-1623OC PMID: 21471098.

25. Turino GM, Ma S, Lin YY, Cantor JO, Luisetti M. Matrix elastin: a promising biomarker for chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine. 2011; 184(6):637–41. doi: 10.1164/rccm.201103-0450PP PMID: 21757624.

26. Rana GS, York TP, Edmiston JS, Zedler BK, Pounds JG, Adkins JN, et al. Proteomic biomarkers in plasma that differentiate rapid and slow decline in lung function in adult cigarette smokers with chronic obstructive pulmonary disease (COPD). Analytical and bioanalytical chemistry. 2010; 397(5):1809–19. doi: 10.1007/s00216-010-3742-4 PMID: 20442988.

27. Eickmeier O, Huebner M, Herrmann E, Zissler U, Rosewich M, Baer PC, et al. Sputum biomarker profiles in cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) and association between pulmonary function. Cytokine. 2010; 50(2):152–7. doi: 10.1016/j.cyto.2010.02.004 PMID: 20811491.

28. Igashimoto Y, Iwata T, Okada M, Satoh H, Fukuda K, Tohda Y. Serum biomarkers as predictors of lung function decline in chronic obstructive pulmonary disease. Respiratory medicine. 2009; 103(8):1231–8. doi: 10.1016/j.rmed.2009.01.021 PMID: 19249197.

29. Pinto-Plata V, Tosio J, Lee K, Bilello J, Mullerova H, De Souza M, et al. Use of proteomic patterns of serum biomarkers in patients with chronic obstructive pulmonary disease: correlation with clinical parameters. Proceedings of the American Thoracic Society. 2006; 3(6):465–6. doi: 10.1513/pats.200603-030MS PMID: 16921105.

30. Suzuki M, Makita H, Ostling J, Konno S, Nagai K, et al. Lower leptin/adiponectin ratio and risk of rapid lung function decline in chronic obstructive pulmonary disease. Annals of the American Thoracic Society. 2014; 11(10):1511–9. doi: 10.1513/Annats201408-351OC PMID: 25372271.

31. Carolan BJ, Kim YI, Williams AA, Kechrish K, Lutz S, Reisdorph N, et al. The association of adiponectin with computed tomography phenotypes in chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine. 2013; 188(5):561–6. doi: 10.1164/rccm.201212-2299OC PMID: 23777325; PubMed Central PMCID: PMC3827701.

32. Kirdar S, Serter M, Ceylan E, Sener AG, Kavak T, Karadag F. Adiponectin as a biomarker of systemic inflammatory response in smoker patients with stable and exacerbation phases of chronic obstructive pulmonary disease. Scandinavian journal of clinical and laboratory investigation. 2009; 69(2):219–24. doi: 10.1080/00365510802474400 PMID: 19646779.

33. Dahl M. Biomarkers for chronic obstructive pulmonary disease: surfactant protein D and C-reactive protein. American journal of respiratory and critical care medicine. 2008; 177(11):1177–8. doi: 10.1164/rccm.200802-225ED PMID: 18487618.

34. Wu H, Yang S, Wu X, Zhao J, Zhao J, Ning Q, et al. Interleukin-33/ST2 signaling promotes production of interleukin-6 and interleukin-8 in systemic inflammation in cigarette smoke-induced chronic obstructive pulmonary disease mice. Biochemical and biophysical research communications. 2014; 450(1):110–6. doi: 10.1016/j.bbrc.2014.05.073 PMID: 24866242.

35. He H, Tao Y, Chen X, Qiu H, Zhu J, Zhang J, et al. High levels of interleukin-6 and 8-iso-prostaglandin in the exhaled breath condensate and serum of patients with chronic obstructive pulmonary disease related pulmonary hypertension. Chinese medical journal. 2014; 127(9):1608–12. PMID: 24791862.

36. Liang R, Zhang W, Song YM. Levels of leptin and IL-6 in lungs and blood are associated with the severity of chronic obstructive pulmonary disease in patients and rat models. Molecular medicine reports. 2013; 7(5):1470–6. doi: 10.3892/mmr.2013.1377 PMID: 23825184.

37. Petersen AM, Penkowa M, Iversen M, Frydelund-Larsen L, Andersen JL, Mortensen J, et al. Elevated levels of IL-18 in plasma and skeletal muscle in chronic obstructive pulmonary disease. Lung. 2007; 185(3):161–71. doi: 10.1007/s00408-007-9000-7 PMID: 17436040.

38. Fuster A, Saulea J, Sala E, Barcelo B, Pons J, Carrera M, et al. Systemic inflammation after inspiratory loading in chronic obstructive pulmonary disease. International journal of chronic obstructive pulmonary disease. 2008; 3(1):149–53. PMID: 18488438; PubMed Central PMCID: PMC2528210.

39. Chan KH, Yeung SC, Yao TJ, Ip MS, Cheung AH, Chan-Yeung MM, et al. Elevated plasma adiponectin levels in patients with chronic obstructive pulmonary disease. The official journal of the International Union against Tuberculosis and Lung Disease. 2010; 14(9):1193–200. PMID: 20819268.
34. Wang M, Huang Y, Liang Z, Liu D, Lu Y, Dai Y, et al. Plasma miRNAs might be promising biomarkers of chronic obstructive pulmonary disease. The clinical respiratory journal. 2014. doi: 10.1111/crj.12194 PMID: 25102970.

35. Akbas F, Coskunpinar E, Aynaci E, Oltulu YM, Yildiz P. Analysis of serum micro-RNAs as potential biomarker in chronic obstructive pulmonary disease. Experimental lung research. 2012; 38(6):286–94. doi: 10.3109/01902148.2012.689088 PMID: 22686440.

36. Csanky E, Ruhl R, Scholtz B, Vasko A, Takacs L, Hempel WM. Lipid metabolite levels of prostaglandin D2 and eicosapentaenoic acid recovered from bronchoalveolar lavage fluid correlate with lung function of chronic obstructive pulmonary disease patients and controls. Electrophoresis. 2009; 30(7):1228–34. doi: 10.1002/elps.200800722 PMID: 19294692.

37. Bowler RP, Jacobson S, Cruickshank C, Hughes GJ, Siska C, Ory DS, et al. Plasma sphingolipids associated with chronic obstructive pulmonary disease phenotypes. American journal of respiratory and critical care medicine. 2015; 191(3):275–84. doi: 10.1164/rccm.201410-1771OC PMID: 25494452.

38. Deja S, Porebska I, Kowal A, Zabek A, Barg W, Pawelczyk K, et al. Metabolomics provide new insights on lung cancer staging and discrimination from chronic obstructive pulmonary disease. Journal of pharmaceutical and biomedical analysis. 2014; 100:369–80. doi: 10.1016/j.jpba.2014.08.020 PMID: 25213261.

39. Scott JA, Duongh M, Young AW, Subbarao P, Gauvreau GM, Grasemann H. Asymmetric dimethylarginine in chronic obstructive pulmonary disease (ADMA in COPD). International journal of molecular sciences. 2014; 15(4):6062–71. doi: 10.3390/ijms15046062 PMID: 24772374; PubMed Central PMCID: PMC4013615.

40. Markouilis N, Gourgoulianis KI, Moulas A, Gerogianni E, Molyvdas AP. Reactive oxygen metabolites as an index of chronic obstructive pulmonary disease severity. Panminerva medica. 2006; 48(4):209–13. PMID: 17215792.

41. Musharraf SG, Mazhar S, Choudhary MI, Rizi N, Atta Ur R. Plasma Metabolite Profiling and Chemometric Analyses of Lung Cancer along with Three Controls through Gas Chromatography-Mass Spectrometry. Scientific reports. 2015; 5:8607. doi: 10.1038/srep08607 PMID: 26712604; PubMed Central PMCID: PMC4339805.

42. Paige M, Burdick MD, Kim S, Xu J, Lee JK, Shim YM. Pilot analysis of the plasma metabolite profiles associated with emphysematous Chronic Obstructive Pulmonary Disease phenotype. Biochemical and biophysical research communications. 2011; 413(4):588–93. doi: 10.1016/j.bbrc.2011.09.006 PMID: 21925153; PubMed Central PMCID: PMC3199021.

43. Ten Hoeve AL, Roda MA, Redegeld F, Folkerts G, Blaock JE, Gaggar A. Proline-glycine-proline as a potential biomarker in chronic obstructive pulmonary disease and cystic fibrosis. Tanaffos. 2012; 11(2):12–5. PMID: 25191408; PubMed Central PMCID: PMC4153190.

44. Antczak A, Ciebiada M, Pietras T, Piotrowski W, Kurmanowska Z, Gorski P. Exhaled eicosanoids and biomarkers of oxidative stress in exacerbation of chronic obstructive pulmonary disease. Archives of medical science: AMS. 2012; 8(2):277–85. doi: 10.5114/aoms.2012.28555 PMID: 22662001; PubMed Central PMCID: PMC3361040.

45. Diaz AA, Valim C, Yamashiro T, Estepar RS, Ross JC, Matsuoka S, et al. Airway count and emphysema assessed by chest CT imaging predicts clinical outcome in smokers. Chest. 2010; 138(4):880–86. doi: 10.1378/chest.10-0542 PMID: 20558554; PubMed Central PMCID: PMC2951760.

46. Bentley AR, Emrani P, Cassano PA. Genetic variation and gene expression in antioxidant related enzymes and risk of COPD: a systematic review. Thorax. 2008; 63(11):956–61. doi: 10.1136/thx.2007.086119 PMID: 18566111; PubMed Central PMCID: PMC3032799.

47. Ning W, Lee J, Kaminiski N, Feghali-Bostwick CA, Watkins SC, Pilewski JM, et al. Comprehensive analysis of gene expression on GOLD-2 Versus GOLD-0 smokers reveals novel genes important in the pathogenesis of COPD. Proceedings of the American Thoracic Society. 2006; 3(6):466. doi: 10.1513/pats.200603-031MS PMID: 16921106.

48. Zhang J, Wang X, Chen Y, Yao W. Exhaled Hydrogen Sulfide Predicts Airway Inflammation Phenotype in COPD. Respiratory care. 2015; 60(2):251–8. doi: 10.1187/respcare.03519 PMID: 25336529.

49. Malerba M, Radaelli A, Olivini A, Damiani G, Ragnoli B, Montuschi P, et al. Exhaled nitric oxide as a biomarker in COPD and related comorbidities. BioMed research international. 2014; 2014:271918. doi: 10.1155/2014/271918 PMID: 24719850; PubMed Central PMCID: PMC3955647.

50. Papaioannou AI, Loukides S, Minas M, Kontogianni K, Bakakos P, Gourgoulianis KI, et al. Exhaled breath condensate pH as a biomarker of COPD severity in ex-smokers. Respiratory research. 2011; 12:67. doi: 10.1186/1465-9921-12-67 PMID: 21600044; PubMed Central PMCID: PMC3120669.

51. Nobakht MGBF, Aliannejad R, Rezaei-Tavirani M, Taheri S, Oskouie AA. The metabolomics of airway diseases, including COPD, asthma and cystic fibrosis. Biomarkers: biochemical indicators of exposure, diseases, including COPD, asthma and cystic fibrosis. Tanaffos. 2012; 11(2):12–5. PMID: 25191408; PubMed Central PMCID: PMC4153190.
response, and susceptibility to chemicals. 2015; 20(1):5–16. doi: 10.3109/1354750X.2014.983167 PubMed: 25403491.

58. Ubhi BK, Cheng KK, Dong J, Janowitz T, Jodrell D, Tal-Singer R, et al. Targeted metabolomics identifies perturbations in amino acid metabolism that sub-classify patients with COPD. Molecular bioSystems. 2012; 8(12):3125–33. doi: 10.1039/c2mb25194a PubMed: 23051772.

59. Chen Q, Park HC, Goligorsky MS, Chander P, Fischer SM, Gross SS. Untargeted plasma metabolite profiling reveals the broad systemic consequences of xanthine oxidoreductase inactivation in mice. PloS one. 2012; 7(6):e37149. Epub 2012/06/23. doi: 10.1371/journal.pone.0037149 PubMed: 22723833; PubMed Central PMCID: PMC3377762.

60. Ismailoglu I, Chen Q, Popowski M, Yang L, Gross SS, Brivanlou AH. Huntingtin protein is essential for mitochondrial metabolism, bioenergetics and structure in murine embryonic stem cells. Developmental biology. 2014; 391(2):230–40. Epub 2014/05/02. doi: 10.1016/j.ydbio.2014.04.005 PubMed: 24780625; PubMed Central PMCID: PMC4109978.

61. Senior RM, Skogen WF, Griffin GL, Wilner GD. Effects of fibrinogen derivatives upon the inflammatory response. Studies with human fibrinopeptide B. The Journal of clinical investigation. 1986; 77(3):1014–9. doi: 10.1172/JCI112353 PubMed: 3005361; PubMed Central PMCID: PMC423507.

62. Mannino DM, Tal-Singer R, Lomas DA, Vestbo J, Graham Barr R, Tetzlaff K, et al. Plasma Fibrinogen as a Biomarker for Mortality and Hospitalized Exacerbations in People with COPD. Chronic obstructive pulmonary diseases. 2015; 2(1):23–34. doi: 10.15326/jcpdpd.2.1.2014.0138 PubMed: 25685850; PubMed Central PMCID: PMC4326107.

63. Wedzicha JA, Seemungal TA, MacCallum PK, Paul EA, Donaldson GC, Bhowmik A, et al. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thrombosis and haemostasis. 2000; 84(2):210–5. PMID: 10959691.

64. Blomback B, Hessel B, Hogg D, Therkildsen L. A two-step fibrinogen—fibrin transition in blood coagulation. Nature. 1978; 275(5680):501–5. PMID: 692730.

65. Eckhardt T, Nossei HL, Hurlet-Jensen A, La Gamma KS, Owen J, Auerbach M. Measurement of desarginine fibrinopeptide B in human blood. The Journal of clinical investigation. 1981; 67(3):809–16. doi: 10.1172/JCI110098 PubMed: 7204556; PubMed Central PMCID: PMC370632.

66. Undas A, Kaczmarek P, Sladek K, Stepien E, Skucha W, Rzeszutko M, et al. Fibrin clot properties are altered in patients with chronic obstructive pulmonary disease. Beneficial effects of simvastatin treatment. Thrombosis and haemostasis. 2009; 102(6):1176–82. doi: 10.1160/TH09-02-0118 PubMed: 19967149.

67. Tapon VF. The role of smoking in coagulation and thromboembolism in chronic obstructive pulmonary disease. Proceedings of the American Thoracic Society. 2005; 2(1):71–7. doi: 10.1513/pats.200407-038MS PubMed: 16113472.

68. Polosa R, Malerba M, Cacciola RR, Morjaria JB, Maugeri C, Prosperini G, et al. Effect of acute exacerbations on circulating endothelial, clotting and fibrinolytic markers in COPD patients. Internal and emergency medicine. 2013; 8(7):567 doi: 10.1172/JCI110098 PubMed: 21660493.

69. Dessi A, Fanos V. Myooinositol: a new marker of intrauterine growth restriction? Journal of obstetrics and gynaecology: the journal of the Institute of Obstetrics and Gynaecology. 2013; 33(8):776–80. doi: 10.3109/01443615.2013.831046 PubMed: 24219712.

70. Han W, Gills JJ, Memmott RM, Lam S, Dennis PA. The chemopreventive agent myooinositol inhibits Akt and extracellular signal-regulated kinase in bronchial lesions from heavy smokers. Cancer prevention research. 2009; 2(4):370–6. doi: 10.1158/1940-6207.CAPR-08-0209 PubMed: 19367371; PubMed Central PMCID: PMC3715041.

71. Sriskantharajah S, Hamblin N, Worsley S, Calver AR, Hessel EM, Amour A. Targeting phosphoinositide 3-kinase delta for the treatment of respiratory diseases. Annals of the New York Academy of Sciences. 2013; 1280:35–9. doi: 10.1111/nyas.12039 PubMed: 23551101.

72. Marwick JA, Chung KF, Adcock IM. Phosphatidylinositol 3-kinase isoforms as targets in respiratory disease. Therapeutic advances in respiratory disease. 2010; 4(1):19–34. doi: 10.1177/1753465809332792 PubMed: 20051446.

73. Dinavahi SS, Nyayapathy S, Perumal Y, Dharmarajan S, Viswanadha S. Combined inhibition of PDE4 and PI3Kdelta modulates the inflammatory component involved in the progression of chronic obstructive pulmonary disease. Drug research. 2014; 64(4):214–9. doi: 10.1055/s-0033-1355411 PubMed: 24105104.

74. Girod S, Galabert C, Lecuire A, Zahl JM, Puchelle E. Phospholipid composition and surface-active properties of tracheobronchial secretions from patients with cystic fibrosis and chronic obstructive pulmonary diseases. Pediatric pulmonology. 1992; 13(1):22–7. PMID: 1589308.

75. Rothwell JA, Fillatre Y, Martin JF, Lyen B, Pujo-Guillot E, Fezeu L, et al. New biomarkers of coffee consumption identified by the non-targeted metabolomic profiling of cohort study subjects. Plos one. 2014;
76. Allred KF, Yackley KM, Vanamala J, Allred CD. Trigonelline is a novel phytoestrogen in coffee beans. The Journal of nutrition. 2009; 139(10):1833–8. doi: 10.3945/jn.109.108001 PMID: 19710155.

77. Jetter A, Kinzig M, Rodamer M, Tomalik-Scharte D, Sorgel F, Fuhr U. Phenotyping of N-acetyltransferase type 2 and xanthine oxidase with caffeine: when should urine samples be collected? European journal of clinical pharmacology. 2009; 65(4):411–7. doi: 10.1007/s00228-008-0597-0 PMID: 19082994.

78. Tang BK, Kadar D, Qian L, Iriah J, Yip J, Kalow W. Caffeine as a metabolic probe: validation of its use for acetylator phenotyping. Clinical pharmacology and therapeutics. 1991; 49(6):648–57. PMID: 2060254.

79. Begas E, Kouvaras E, Tsakalof A, Papakosta S, Asprodini EK. In vivo evaluation of CYP1A2, CYP2A6, NAT-2 and xanthine oxidase activities in a Greek population sample by the RP-HPLC monitoring of caffeine metabolic ratios. Biomedical chromatography: BMC. 2007; 21(2):190–200. doi: 10.1002/bmc.736 PMID: 17221922.

80. Grygiel JJ, Birkett DJ. Cigarette smoking and theophylline clearance and metabolism. Clinical pharmacology and therapeutics. 1981; 30(4):491–6. PMID: 7285483.